Articles tagged with Brain Tumors
Researchers have developed a noninvasive brain biopsy technique using ultrasound and microbubbles to access brain tissue without surgery. The technique increases circulating tumor DNA by 1.6- to 5.6-fold, providing valuable genetic information for treatment decisions.
Scientists from German Cancer Research Center successfully tested transgenic T cells against glioblastoma, a type of aggressive brain tumor. The T cells were engineered to recognize and kill cancer cells, showing a greater than 40% response rate in treated mice.
Researchers have developed a peptide vaccine targeting a specific mutation in the histone protein H3K27M, common in diffuse midline gliomas. The vaccine induced immune responses in patients and led to tumor regression in some cases.
The INSIGhT trial has reported initial results, with patients on abemaciclib and neratinib experiencing longer progression-free survival than those receiving standard therapy. The adaptive platform trial uses Bayesian Adaptive Randomization to identify therapies that benefit patients more efficiently.
Researchers at the University of Nottingham have developed a new way to target and kill glioblastoma cells, a type of brain cancer with a low five-year survival rate. The breakthrough uses bio-nanoantennae to induce programmed cell death in cancer cells via electrical stimulation.
Researchers at UTSA are studying the bioactive properties of Sweet Annie, a plant used in traditional Chinese medicine for over 2,000 years. The study reveals that arteannuin B from the plant has anti-COVID and anti-glioblastoma properties, offering new avenues for targeted therapy.
Researchers have developed a device that can be implanted into tumors during surgery to test new treatments, providing unprecedented insight into the effects of drugs on glioma tumors. The device, which is designed to be used during standard of care surgery, caused no adverse effects on patients in a phase 1 clinical trial.
Researchers developed a molecular test to identify brain tumors by analyzing genetic material in cerebrospinal fluid. The Real-CSF test correctly identified 67% of cancerous and 96% of noncancerous brain lesions, outperforming standard cytology methods.
Researchers at UCLA Jonsson Comprehensive Cancer Center aim to overcome brain tumor's limited treatment options with ERAS-801, a brain-penetrant inhibitor showing promise in preclinical models. The team is testing the treatment in early clinical trials for patients diagnosed with glioblastoma.
Researchers found that tumors with metastasis to the brain respond better to immunotherapy due to effective priming outside the brain. Glioblastoma, an aggressive brain cancer, does not respond well due to impaired priming step.
A new study from the University of Michigan Department of Neurosurgery and Rogel Cancer Center shows promising early results that a therapy combining cell-killing and immune-stimulating drugs are safe and effective in extending survival for patients with gliomas, a highly aggressive form of brain cancer. The treatment improved survival...
A pioneering study published in Cancer Cell finds that brain metastasis alters the brain's chemistry and disrupts neuronal communication. Researchers discovered a molecule, EGR1, that may play a role in this process, paving the way for potential drug development to alleviate neurocognitive effects.
Researchers at Kanazawa University found a link between nuclear pore complex alterations and glioblastoma. They demonstrated that NUP107 proteins overexpression degrades the function of p53, a crucial cancer-preventing protein. Further studies are needed to uncover the molecular pathways at play.
Recent research on gamma delta T cells has made significant progress in understanding their role in antitumor immune response. Key findings include the identification of various hidden mechanisms and a strong association between tumor-infiltrating gamma delta T cells and patient survival.
Researchers at Michigan Medicine have discovered a potential treatment for diffuse midline glioma, a type of childhood brain tumor with no effective treatments. The compound ONC201 nearly doubled survival rates in patients with the disease, and the underlying mechanism behind its success has been explained.
Researchers find immunotherapy treatment anti-CTLA-4 leads to greater survival in mice with glioblastoma and discover new way cells kill cancer by triggering microglia, specialized immune cells in the brain. This breakthrough could lead to more effective treatments for human brain cancer.
Researchers at Uppsala University developed a new method to identify mutations in childhood brain tumors, medulloblastoma. The study found that these mutations can affect how cancer cells respond to certain drugs, suggesting a potential for precision medicine.
Researchers investigated H3K27me3 expression patterns in pediatric brain tumors, finding a global loss of this epigenetic mark in diffused midline glioma (DMG). This loss was associated with high relapse rates and poor survival, highlighting the potential for targeting H3K27me3 as an epigenetically guided cancer therapy.
A study by Dana-Farber Cancer Institute researchers found that gliomas can arise from epigenetic changes, which affect gene activity without altering DNA sequence. The findings pinpoint two genes, an oncogene and a tumor suppressor, whose activities are epigenetically altered in human gliomas.
Researchers have identified a new therapeutic target for glioblastoma brain cancer by finding that the 'don't eat me!' signal sent by cancer cells can be blocked using antibodies. This breakthrough suggests that existing immunotherapies may be effective against glioblastomas if the receivers on macrophages are switched off.
A new study published in Brain Communications found that cognitive reserve can protect brain function in patients with brain tumors. The research revealed that higher levels of education, occupation, and urban environment are associated with improved neuropsychological performance.
Researchers at Tokyo Institute of Technology developed a novel boron agent that selectively accumulates in brain tumor cells, exhibits enhanced blood retention, and can be administered at low doses. The agent, PBC-IP, shows promising results in preclinical studies, highlighting its potential for radiotherapy in treating glioblastoma.
Researchers at Mass General Cancer Center treated 16 patients with a BRAF/MEK inhibitor, resulting in a 91% reduction in tumor size and complete response in all patients who received one or more cycles of therapy. The treatment showed unprecedented success in targeting brain tumors using precision medicine approaches.
Researchers at Nanyang Technological University discover ponatinib, an existing cancer drug, can block key steps in alternative lengthening of telomeres (ALT) mechanism. This could lead to new treatment options for ALT cancers, which currently lack targeted therapies.
An AI tool called CHARM rapidly decodes a brain tumor's DNA to determine its molecular identity during surgery. This information enables neurosurgeons to make informed decisions about how much brain tissue to remove and whether to use tumor-killing drugs directly into the brain.
Researchers at Sylvester Comprehensive Cancer Center found that the ancient retrovirus HML-2 alters stem cell programming by activating a gene-regulating protein called OCT4, contributing to glioblastoma formation and aggressiveness.
Researchers have developed a technology to capture and release cell-free DNA from urine using nanowire surfaces, successfully detecting IDH1 mutation in glioma patients. This method opens possibilities for the detection of other tumor mutations and could revolutionize cancer diagnosis.
A collaborative study by researchers at the University of Ottawa and McMaster University has made a groundbreaking discovery linking different types of cancers to their embryonic origins. The team found that drugs targeting specific embryonic pathways can effectively treat various tumors, including brain, colon, and leukemia cancers.
Three University Hospitals and Case Western Reserve University research teams received $50,000 Collaborative Science Pilot Awards to explore innovative research projects. The awards aim to increase competitiveness and capacity for major external funding opportunities in key areas such as cancer, brain health and genetics.
Research suggests that glioblastoma cells possess large-scale coordination, allowing them to respond unison to therapies. Disrupting this organization may result in more powerful treatments for brain tumors.
Researchers at TUM developed a new approach to measure human brain activity using microelectrodes and awake brain surgery. They found individual neurons specialize in handling specific numbers, providing insights into cognitive functions and developing solutions for brain function disorders.
A UK-wide study found that non-functioning pituitary microadenomas (NFPA) are more likely to shrink or disappear than grow within three years of monitoring. The study suggests that clinical guidelines should be changed, and a single scan three years after initial detection would be a safe and cost-effective way to manage NFPAs.
Researchers found that combining radiation with a genetically engineered oncolytic vaccinia virus improved treatment outcomes for glioblastoma brain tumors in mice. The combination showed a 15% cure rate and 62% rejection of new cancer cells, outperforming radiation alone.
Researchers have made a significant finding in detecting brain tumors by exploiting folate receptors. Folate receptor expression is significantly higher in glioma tissue compared to adjacent healthy brain tissue, presenting a promising target for future treatments.
Researchers have identified a potential breakthrough in glioblastoma treatment, combining a novel viral therapy with a checkpoint inhibitor to attack tumor cells. In phase 2 trials, around 10% of patients showed significant tumor shrinkage and improved overall survival, offering hope for better treatment options.
A new study from Wake Forest University School of Medicine and Atrium Health Levine Cancer Institute highlights improved outcomes for patients treated with preoperative SRS, particularly in rates of tumor recurrence, meningeal disease, and adverse radiation effects. The two-year cavity local recurrence rate was 13.7%, the two-year meni...
Researchers found that rare brain tumor patients struggle to access therapy and experience devastating psychological impact after diagnosis. The study calls for improved mental health services and specialized support for these patients.
A new targeted therapy drug vorasidenib has been shown to extend treatment time without worsening glioma in people with IDH1 and IDH2 mutations. The study suggests a possible new treatment option for slow-growing but deadly brain tumors, delaying chemotherapy and radiation.
Cancer cells in brain tumors produce lipids at higher rates than surrounding healthy tissue, offering clues for treatment strategies. The study provides insights into the unique biochemical processes fueling cancer growth in the brain.
Researchers have created an open-source, reproducible analysis platform for pediatric brain tumors, providing a cloud-based resource for comprehensive data on the disease. The platform contains genomic and clinical data from over 1,000 pediatric brain tumors and 22 patient-derived cell lines.
Researchers at the University of Gothenburg have developed a new blood test that can measure biomarkers in the blood before and after neurosurgery, correlating with the extent of brain injury. The study found that high levels of certain markers may indicate damage that could cause cognitive problems for patients in the long term.
Researchers found that formalin fixation does not significantly alter the polarimetric properties of brain tissue, making it suitable for training machine-learning models. The study suggests that formalin-fixed brain tissue specimens can provide high-quality data for rapid and accurate diagnostic imaging in surgery.
A recent study led by UCLA researchers has identified a potential new strategy for treating glioblastoma by targeting a specific metabolic process in cancer cells. The study found that disrupting this process could make glioblastoma cells more vulnerable to cell death, offering hope for new treatment options.
Researchers at the University of Gothenburg have developed a method to kill glioblastoma brain tumours by blocking stress in cancer cells. The treatment, which involves inserting a specially developed molecule into cells, shows promising results with no side effects.
A clinical trial combining TVB-2640 and bevacizumab showed a six-month progression-free survival improvement in patients with recurrent high-grade glioblastoma, warranting further study. The treatment's side effects were mild, but the overall survival of participants was not statistically significant compared to historic controls.
A multi-institutional team of experts is studying how to use focused ultrasound to create a temporary gateway through the blood-brain barrier to deliver cancer medicine. Researchers aim to develop a personalized medicine approach in which they can test drugs on patient tumors and predict treatment effectiveness.
Researchers have found that craniospinal radiation can control metastasis in diffuse midline gliomas, leading to improved treatment options for patients. The study suggests that this approach may lead to long-term survival and potentially curative effects for these children.
A Phase I/II clinical trial combining intratumoral delivery of an engineered oncolytic virus with subsequent immunotherapy improved survival outcomes in a subset of patients with recurrent glioblastoma. The study demonstrated the combination was well-tolerated, with no dose-limiting toxicities.
Researchers developed a novel combination therapy that eradicates tumors in select patients, with prolonged survival rates. The therapy has shown promise in treating glioblastoma, a notoriously difficult-to-treat primary brain cancer.
Brain cancer cells use mitochondria from healthy astrocytes to boost energy production and amplify cancer stem cells, making glioblastoma more deadly and difficult to treat. Researchers discovered that acquiring mitochondria is a common process in glioblastoma, with implications for developing new treatments.
Research reveals that brain tumor cells communicate with astrocytes through microtubes, transferring mitochondria to enhance growth. This connection increases treatment resistance and tumorigenicity in glioblastoma tumors.
Glioblastoma steals cognitive faculties as it spreads, but its insidious ability to infiltrate neighboring networks may be its undoing. Researchers found neural activity can restructure connections in surrounding tissue, causing decline. The drug gabapentin blocks this growth-causing activity in mice with glioblastoma.
A multi-institutional phase 3 clinical trial found that a cancer stem cell test can accurately decide more effective treatments and lead to increased survival for patients with recurrent glioblastoma. ChemoID, a CLIA-accredited diagnostic test, was used to select chemotherapy treatments, resulting in significantly lower risk of death a...
Researchers identified three novel dual-purpose therapeutic targets using PandaOmics, which could treat both aging and glioblastoma multiforme. The target hypotheses include cyclic nucleotide gated channel subunit alpha 3 (CNGA3), glutamate dehydrogenase 1 (GLUD1) and sirtuin 1 (SIRT1).
Three high school students co-authored a paper using AI engine PandaOmics to discover new therapeutic targets for glioblastoma multiforme, a common and aggressive malignant brain tumor. The study identified three genes strongly correlated with both aging and glioblastoma as potential therapeutic targets.
Scientists successfully opened the blood-brain barrier using a novel ultrasound device, delivering chemotherapy to treat glioblastoma patients. The treatment increased drug concentrations by 4-6 times and was safe and well-tolerated.
A new study by St. Jude Children's Research Hospital found that children with supportive environments fared better than those living in neighborhoods with economic hardship. Higher EHI scores were associated with lower cognitive abilities and greater decline after treatment, especially in math skills.
Researchers at Sanford Burnham Prebys have discovered that a 3D view of the genome can reveal genes in tumors that may be future targets for therapy. By visualizing how the genome is organized and arranged within tumor cells, they were able to identify new candidate targets for treatments.
Neurologist Soma Sengupta introduces the concept of integrative neuro-oncology, combining conventional treatments with alternative therapies to enhance patient well-being. Her approach prioritizes the unique needs of brain tumor patients and their caregivers, promoting a holistic understanding of medicine.
Scientists have created a detailed map of human spinal cord cell formation, shedding light on how injuries and diseases arise. The study's findings hold promise for developing new therapies for spinal cord injuries and diseases like ALS.